Denali Therapeutics Inc. announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, which evaluates Denali?s eIF2B agonist DNL343. Regimen G is co-led by Suma Babu, MBBS, MPH, and Sabrina Paganoni, MD, PhD, physician investigators at the Healey & AMG Center for ALS at MGH.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.24 USD | -2.97% | +8.41% | -5.68% |
05-08 | Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating | MT |
05-08 | Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.68% | 2.89B | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.73% | 22.28B | |
-11.90% | 22.41B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial